Clinical Trial Results: Positive results from clinical trials of UCB's drugs typically boost the stock price, while negative or inconclusive results can lead to a decline.

Regulatory Approvals: Approval of new drugs or expanded use of existing drugs by regulatory agencies like the FDA (US) or EMA (Europe) often increases investor confidence and drives up the price.

Competition: The presence of competing drugs or therapies in the market can affect UCB's market share and revenue, potentially impacting its stock price. Strong competition may lead to lower prices.

Patent Protection: Expiry of patents on key drugs can lead to generic competition, significantly reducing revenue and impacting the stock. Strong patent portfolios are positive for the stock.

Financial Performance: UCB's revenue, earnings, and profitability directly influence investor perception. Strong financial results generally lead to higher stock prices.

Market Conditions: Broad market trends, such as economic growth or recession, can impact investor sentiment and the overall performance of the stock market, affecting UCB as well.

Investor Sentiment: News, rumors, and general market psychology can influence buying and selling pressure on UCB stock, leading to price fluctuations.